| Literature DB >> 24300369 |
Svetlana Ibrić, Jelena Djuriš, Jelena Parojčić, Zorica Djurić.
Abstract
Implementation of the Quality by Design (QbD) approach in pharmaceutical development has compelled researchers in the pharmaceutical industry to employ Design of Experiments (DoE) as a statistical tool, in product development. Among all DoE techniques, response surface methodology (RSM) is the one most frequently used. Progress of computer science has had an impact on pharmaceutical development as well. Simultaneous with the implementation of statistical methods, machine learning tools took an important place in drug formulation. Twenty years ago, the first papers describing application of artificial neural networks in optimization of modified release products appeared. Since then, a lot of work has been done towards implementation of new techniques, especially Artificial Neural Networks (ANN) in modeling of production, drug release and drug stability of modified release solid dosage forms. The aim of this paper is to review artificial neural networks in evaluation and optimization of modified release solid dosage forms.Entities:
Year: 2012 PMID: 24300369 PMCID: PMC3834927 DOI: 10.3390/pharmaceutics4040531
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Schematic representation of biological neuron.
Figure 2Schematic representation of artificial neuron.
Figure 3Schematic representation of feed-forward neural network.
Steps in the supervised network training and usage.
|
|
|
Data is presented to the network Network computes an output Network output is compared to desired output Network weights are modified to reduce error |
|
|
|
Present new, unseen data to the network Network computes an output based on its training |
Figure 4Example of Multilayer perceptron (MLP) network architecture with four layers (first layer with four neurons, second and third layers with three neurons and fourth layer with one neuron).
Figure 5Example of generalized regression neural network (GRNN) architecture.
Figure 6Topology of Elman neural network.
Figure 7Schematic representation of inputs and outputs for the optimization of matrix tablets [30].
Figure 8Flow diagram for the network architecture selection [30].
Figure 9Schematic representation of MLP network.
Observed versus MLP predicted values for test formulations.
| Formulation | Observed values Porosity (%) and tensile strength (MPa) | Predicted values Porosity (%) and tensile strength (MPa) ( |
|---|---|---|
| Test 1 | 19.55 ± 0.49 1.304 ± 0.042 | 20.34 ± 0.78 1.313 ± 0.155 |
| Test 2 | 17.55 ± 0.55 1.661 ± 0.035 | 17.33 ± 0.78 1.539 ± 0.155 |
Figure 10Schematic representation of gamma memory dynamic neural network (GMDNN).
Figure 11Representation of recurrent one layer dynamic neural network (OLDNN): (a) Peltarion® software layout and (b) network’s schematic representation.
Figure 12Representation of Elman dynamic neural network.
Formulation, characterization and optimization of modified release solid dosage forms are listed, with respect to inputs/outputs selected, type of the network used, and the authors(year) of performed studies.
| Formulation, characterization and optimization of modified release formulation | ||
|---|---|---|
| Inputs/outputs/aim | Network type | Authors, year |
| Design of controlled release formulations. Varying formulation variables were used as inputs and | MLP | Chen, 1999 [ |
| Optimization of diclofenac sodium sustained release matrix tablets. Trained model was used to predict release profiles and to optimize the formulation composition. | MLP | Zupancic Bozic, 1997 [ |
| Design of extended release aspirin tablets. The amount of Eudragit® RS PO/Eudragit® L-polymer and compression pressure were selected as inputs, whereas | GRNN | Ibric, 2002, 2003, 2007 [ |
| Prediction of drug dissolution profiles. Inputs for the network training were the matrix forming agents’ ratio, the time point of the measurement of percent dissolved, and the difference between the release rate of the preceding two time points of the predicted profile. | MLP | Peh, 2000 [ |
| Investigation of controlled drug release. Drug fraction and time were used as network inputs and | MLP | Reis, 2004 [ |
| Prediction of dissolution profiles for matrix controlled release theophylline pellet preparation. Inputs for the network training were the matrix forming agents’ ratio, and the time point of the measurement of percent dissolved; | EDNN | Goh, 2002 [ |
| Modeling of diclofenac sodium release from Carbopol 71G matrix tablets. Polymer and binder content were inputs, while | MLP | Ivic, 2010a [ |
| Modeling of diclofenac sodium release from polyethylene oxide matrix tablets. Polymer weight ratio and compression force were used as inputs, whereas | MLP, GMDNN, OLDNN | Petrović, 2009 [ |
| Drug release control and system understanding of sucrose esters matrix tablets. Networks inputs were HLB values of sucrose esters (SEs), SEs concentration, tablet volume, tablet porosity and tablet tensile strength. | MLP | Chansanroj, 2011 [ |
| A number of unique ANN configurations are presented, that have been evaluated for their ability to determine an IVIVC from different formulations of the same product. | MLP, GRNN, RNN | Dowell, 1999 [ |
| Development of level A | GRNN | Parojčić, 2007 [ |
| Prediction of relative lung bioavailability and clinical effect of salbutamol when delivered to healthy volunteers and asthmatic patients from dry powder inhalers (DPIs). Training of the ANN network was performed using | MLP | De Matas, 2008 [ |
| Prediction of kinetics of doxorubicin release from sulfopropyl dextran ion-exchange microspheres. Three independent variables, drug loading level, concentration of NaCl and CaCl2 in the release medium were used as the ANN inputs and the fractional release of doxorubicin at four different time points as the outputs. | MLP, HNN | Li, 2005 [ |
| Prediction of drug release profiles in transdermal iontophoresis. Neural networks inputs were the process conditions of pH, ionic strength and current, as well as the time point. The output was the predicted permeation rate of the drug (diclofenac sodium). | RBFNN | Lim, 2003 [ |
| Optimization of drug release from compressed multi unit particle system (MUPS) using generalized regression neural network (GRNN) | GRNN | Ivic, 2010b [ |
Abbreviations: MLP, Multilayered Perceptron; GRNN, Generalized Regression Neural Network; RBFNN, Radial Basis Function Neural Network; EDNN, Elman Dynamic Neural Network; GMDNN, Gamma memory Dynamic Neural Network; OLDNN, One Layer Dynamic Neural Network; HNN, Hierarchical Neural Network.